A&A Clinical Research

02/20/2026

Do you have sleep apnea and a BMI ≥ 27 kg/m²?
A clinical research center in Brampton is currently recruiting participants for a study evaluating an investigational drug for adults living with obesity and obstructive sleep apnea.
You may qualify if you:
✅ Are 18+ years of age
✅ Have a BMI ≥ 27 kg/m²
✅ Diagnosed with moderate-to-severe sleep apnea (AHI ≥ 15)
✅ History of at least one unsuccessful attempt at weight loss by diet and exercise
✅ Not currently diagnosed with Type 1 or Type 2 Diabetes
Eligible participants will receive study-related procedures and compensation for time and travel associated with study visits.
Contact us to see if you qualify: [email protected]

03/26/2025

A&A Clinical Research is conducting a clinical trial to evaluate the efficacy and safety of an investigational Salbutamol Inhaler for participants with asthma.

Eligibility:
• Are 18 years of age or older.
• Having asthma for ≥ 6 months.
• Current non-smokers, who have not used any to***co or va**ng products within 12 months of the start of the study,

Eligible participants will receive study related care and investigational medication at no cost, and may be reimbursed for study related travel.

Sign up here: https://aaaclinicalresearch.com/trial/asthma-2/

For more information, call: 905-458-9033

02/15/2025

Orangeville just got a major healthcare upgrade! 🎉 The Alder Square Medical Centre & Pharmacy is here to bridge long-standing gaps in healthcare access, offering modern examination rooms, an onsite lab, and advanced diagnostics—all in one convenient location.

Led by Monika Arora and her team, the full-service pharmacy ensures a seamless healthcare experience for the community. This milestone was celebrated by Hon. Mayor Lisa Post and MPP Sylvia Jones, who emphasized the centre’s role in expanding primary care and advancing clinical research through A&A Clinical Research.

💡 What makes this facility special?
✅ High-quality, accessible care for Orangeville residents
✅ Clinical research opportunities to shape the future of medicine
✅ A hub for innovation and community well-being

This expansion is more than just a clinic—it’s a commitment to a healthier, brighter future. 💙

📍 Visit Alder Square Medical Centre & Pharmacy today and experience the future of healthcare in Orangeville!



Read more: https://aaaclinicalresearch.com/aa-clinical-research-expands-to-orangeville-transforming-access-to-healthcare/

11/18/2024

The article highlights the growing potential of anti-obesity medications like GLP-1s but also sheds light on significant barriers like inadequate healthcare support, and limited access.

Addressing these barriers requires a multi-faceted approach, including informed healthcare professionals and accessible treatments. Through our clinical trials, A&A Clinical Research is committed to advancing evidence-based solutions and empowering patients to contribute to the future of obesity care.

With the recent and ongoing wave of innovation in anti-obesity medication, obesity as a therapy area has re-entered the spotlight. Questions about efficacy, long-term effectiveness and reimbursement of the new therapies has drawn renewed attention to challenges of effective long-term weight loss....

11/17/2024

A&A Clinical Research is conducting a clinical trial to evaluate the efficacy and safety of an investigational Salbutamol Inhaler for participants with uncontrolled asthma.

Eligibility:
• Are 18 years of age or older.
• Having asthma for ≥ 6 months.
• Current non-smokers, who have not used any to***co or va**ng products within 12 months of the start of the study.

Eligible participants will receive study related care and investigational medication at no cost, and may be reimbursed for study related travel.

For more information call: 905-458-9033 or sign up at: https://aaaclinicalresearch.com/trial/asthma-2/

11/12/2024

We are honoured to recognize Dr. Salma Seedat, a dedicated family physician and sub-investigator, who recently completed her first marathon at the Scotiabank Toronto Waterfront Marathon! 🏅 Dr. Seedat’s journey from her first 10K to crossing the marathon finish line has been fuelled by the same commitment and passion she brings to her patients and clinical research.

From 4:30 a.m. training runs to balancing her demanding career, Dr. Seedat’s determination exemplifies resilience and dedication. She’s a true role model, inspiring patients, colleagues, and her community to pursue their health and wellness goals.

Join us in celebrating Dr. Seedat’s incredible achievement and her commitment to health, well-being, and clinical research. As she says, “Don’t dream of winning; train for it.” 💪

Read more: https://aaaclinicalresearch.com/a-journey-of-resilience-and-inspiration-from-medicine-to-marathon/

09/15/2024

Clinical trials help advance medical knowledge, ensuring new therapies are safe before being widely used. Your participation can contribute to medical breakthroughs! Learn more: (link in bio)

09/09/2024

Great insights from Everyday Health

Any of these symptoms could indicate one of several types of heart disease: https://bit.ly/3XipwmT

09/08/2024

Migraines can turn everyday tasks into challenging hurdles 🤕💡. Our migraine clinical trials focus on treatments aimed at preventing and reducing migraine frequency and severity. If migraines disrupt your daily life, consider joining our studies. Your participation could help advance migraine management. Eligible participants receive study-related medication and medical care at no cost, with compensation for each completed visit. (link in bio)

09/02/2024

Asthma can often feel like an invisible barrier to breathing freely and living fully 🌬️💪. We’re conducting a clinical trial exploring a new treatment for those with uncontrolled asthma. All study-related care, including the study medication, will be provided at no cost, and compensation will be offered to eligible candidates. Consider joining. (link in bio)

09/01/2024

At the European Society of Cardiology (ESC) Congress 2024, results from the SELECT trial were presented, highlighting the potential of semaglutide in treating obesity-related diastolic heart failure (HFpEF). Semaglutide, which is already utilized in managing obesity, type 2 diabetes, and cardiovascular risk, is also being investigated for its application in chronic kidney disease (CKD) and peripheral artery disease (PAD).

Presented by Dr. Subodh Verma from the University of Toronto, the trial highlighted these findings:

🔹 Semaglutide led to significant reductions in body weight, waist circumference, and hsCRP levels, particularly among female participants.
🔹 Females with overweight or obesity and atherosclerotic cardiovascular disease (ASCVD) showed a lower risk of major adverse cardiovascular events (MACEs) than males, despite differences in LDL-C, hsCRP, and BMI.
🔹 Although the absolute risk reduction (ARR) was higher in males, semaglutide’s efficacy across cardiovascular, metabolic, and kidney outcomes was consistent across sexes.
🔹 The study also addressed the safety profile of semaglutide, noting that gastrointestinal adverse events were comparable between males and females.

These findings contribute to the understanding of semaglutide’s role in managing complex obesity-related conditions and indicate the need for further research into its broader therapeutic applications.



https://lnkd.in/gtU_AbZG